PharmaEngine

PharmaEngine Tangible Book Value per Share

The Tangible Book Value per Share of PharmaEngine (4162.TWO) as of Nov 14, 2026 is 33.81 TWD. In the previous year, Tangible Book Value per Share was 37.05 TWD — a change of -8.75% (lower).

Tangible Book Value per Share

33.81TWD

YoY

-8.75%

Last updated:

Tangible Book Value per Share of PharmaEngine is 2025 33.81 TWD. Tangible Book Value per Share of PharmaEngine was 2024 37.05 TWD. It decreases by -8.75% lower compared to the previous year.

The PharmaEngine Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
25.35 TWD
Jan 1, 2019
23.91 TWD
Jan 1, 2020
27.53 TWD
Jan 1, 2021
27.03 TWD
Jan 1, 2022
26.56 TWD
Jan 1, 2023
26.50 TWD
Jan 1, 2024
37.05 TWD
Jan 1, 2025
33.81 TWD
The PharmaEngine Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
33.81TWD-8.75%
37.05TWD+39.81%
26.50TWD-0.22%
26.56TWD-1.74%
27.03TWD-1.80%
27.53TWD+15.15%
23.91TWD-5.71%
25.35TWD-5.55%
26.84TWD+2.95%
26.07TWD+20.24%
21.68TWD+7.93%
20.09TWD+6.81%
18.81TWD+52.44%
12.34TWD+129.78%
5.37TWD+621.84%
0.74TWD+620.83%
0.10TWD-70.89%
0.35TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Tangible Book Value per Share of PharmaEngine is 33.81 TWD in 2025.

Tangible Book Value per Share of PharmaEngine changed from 37.05 TWD to 33.81 TWD, representing a -8.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PharmaEngine

All Key Metrics — PharmaEngine